[redacted]

Hindustan
BIOSCIENCES LTD

To,

Date: 31.08.2026

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 31.08.2026

Ref: Company's Letter dated 26.08.2026

Unit: Hindustan Bio Sciences Limited (BSE Scrip Code:532041)

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Hindustan Bio Sciences Limited in its meeting held on Monday, 31.08.2026 at 4:00 p.m. at the Registered Office of the Company at has inter-alia considered and approved the following:

1. Proposal for Scheme of Reduction of Capital of the Issued, Subscribed and Paid-up Share capital of the Company under Section 66 and other applicable provisions of the Companies Act, 2013 ("Act") ("Scheme"), providing for the reduction and re-organisation of the capital of the Company.

   The Scheme, as approved by the Board, shall be made available on the website of the Company after filing the same with BSE Limited. The approval of the Scheme by the Board is subject to receipt of the necessary approvals from the shareholders of the Company, the Hyderabad Bench of the National Company Law Tribunal (NCLT) and such other statutory and regulatory approvals as may be required.

2. Notice for convening Annual General Meeting (AGM) for the Financial Year 2025-26.

   In compliance with Regulation 30 of the Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 necessary disclosure is enclosed as **Annexure-A.**

The meeting concluded at 4:30 p.m.

Thanking you.

Yours sincerely,

For Hindustan Bio Sciences Limited

Hindustan Bio Sciences Limited
Hyderabad

J V R Mohan Raju
Managing Director
DIN: 00060800
Encl. as above

HINDUSTAN BIOSCIENCES LTD.
#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564

Hindustan
BIOSCIENCES LTD

Annexure-A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 as issued on July 11, 2023, and updated on January 30, 2026.

Details and reasons for Restructuring	The proposed Scheme of capital reduction of the issued, subscribed and paid-up share capital of the Company contemplates the cancellation and extinguishment of 56,37,940 (Fifty-six lakhs thirty-seven thousand nine hundred forty only) fully paid-up equity shares of ₹ 2 (Rupees Two only) each on a pro-rata basis. The cancellation of these equity shares is being undertaken to realign and reorganise the equity capital structure of the Company, thereby better reflecting the current capital base. The Board of Directors believes that this capital reduction is necessary to set off the past year(s) accumulated losses to give a true and fair view of the Company's financial position.
Quantitative and/or qualitative Effect of Restructuring	The proposed capital reduction will result in a reduction of the Company's paid-up equity share capital from Rs. 2,05,01,600/- (Rupees Two Crores Five Lakhs One Thousand Six Hundred Only) divided into 1,02,50,800 (One Crore Two Lakhs Fifty Thousand Eight Hundred Only) equity shares of Rs. 2/- (Rupees Two only) each to Rs. 92,25,720/- (Rupees Ninety-Two Lakhs Twenty-Five Thousand Seven Hundred Twenty only) divided into 46,12,860 (Forty-Six Lakhs Twelve Thousand Eight Hundred Sixty Only) equity shares of Rs. 2/- (Rupees Two only) each, by cancelling and extinguishing 56,37,940 (Fifty-six lakhs thirty-seven thousand nine hundred forty only) equity shares on a pro-rata basis. As a consequence of this cancellation, the Company proposes to set off Rs. 1,12,75,880/- (Rupees One Crore Twelve Lakhs Seventy-Five Thousand Eight Hundred Eighty Only) out of the total accumulated losses of Rs.1,22,41,849/- (Rupees One crore twenty-two lakhs forty-one thousand eight hundred forty-nine Only) against the reduced share capital resulting in a significant reduction of accumulated losses lying in the Company's balance sheet. Further as a part of reorganisation of capital, the existing face value of the shares after reduction of capital i.e., Rs. 2/- per share will be consolidated into face value of Rs. 10/- per share, i.e., every 5 Equity shares of Rs. 2/- each after reduction of capital will be consolidated into 1 equity share of Rs. 10/- each. It is proposed to effect the reduction of share capital by reducing the number of equity shares from 1,02,50,800 Equity Shares of Rs. 2/- each to 46,12,860 Equity Shares of Rs. 2/- each and subsequently effect the consolidation from 46,12,860 Equity Shares of Rs. 2/- each to 9,22,572 Equity Shares of Rs. 10/- each.

HINDUSTAN BIOSCIENCES LTD.
#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.
+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564

	As a result of such proposed reduction and consolidation in Issued, Subscribed and Paid-Up Equity Share Capital, the shareholders of the Company on the record date will get 9 (Nine) equity share of Rs.10/- (Rupees Ten Only) each fully paid-up against 100 (Hundred) equity shares of Rs.2/- (Rupees Two Only) each fully paid up. The fractional entitlements, if any, shall be rounded off to one share and the same would be allotted to the respective shareholders. Simultaneously, the increase in the number of shares due to rounding off will be forgone by Mr. Venkata Rama Mohan Raju Jampana, Promoter of the Company thus keeping the paid-up Share Capital intact to Rs. 92,25,720/- (Rupees Ninety-Two Lakhs Twenty-Five Thousand Seven Hundred Twenty only) divided into 9,22,572 Equity Shares of Rs. 10/- each The restructuring is intended to improve the net worth of the Company and present a clearer and more accurate depiction of its financial position by eliminating a substantial portion of past losses. Qualitatively, the capital structure will be simplified, with the relative shareholding percentages of all continuing shareholders remaining unchanged, and no consideration paid to shareholders for the cancelled shares. This will enhance the financial ratios and overall capital efficiency of the Company without impacting the economic interest of existing shareholders.
Details of Benefit, if any, to the promoter/ promoter group /group companies from such proposed Restructuring;	No benefit will accrue to the promoter/Promoter group/group companies from the proposed scheme of capital reduction.
Brief details of change in shareholding pattern (if any) of all entities.	After cancellation of 56,37,940 (Fifty-six lakhs thirty-seven thousand nine hundred forty only) equity shares on a pro-rata basis, the total paid-up share capital of the Company will be Rs. 92,25,720/- (Rupees Ninety-Two Lakhs Twenty-Five Thousand Seven Hundred Twenty only) divided into 46,12,860 (Forty-Six Lakhs Twelve Thousand Eight Hundred Sixty Only) equity shares of Rs. 2/- (Rupees Two only) each and thereafter 9,22,572 Equity Shares of Rs. 10/- each after consolidation. The shareholding pattern post reduction will be adjusted so that the percentage shareholding of each existing shareholder remains the same as before the reduction.

Hindustan Bio Sciences Limited
Hyderabad